Corvus Pharmaceuticals Advances Soquelitinib Trials with $215M Cash Runway — Corvus Pharmaceuticals, Inc.

Event summary

Corvus reported $215.2M in cash, cash equivalents, and marketable securities as of June 30, 2026, providing runway into Q2 2028.
Soquelitinib Phase 1 trial data for atopic dermatitis presented at the Society for Investigative Dermatology (SID) annual meeting showed safety and positive efficacy results.
Corvus is enrolling patients in a Phase 3 trial for relapsed/refractory PTCL and a Phase 2 trial for atopic dermatitis, with Angel Pharmaceuticals conducting a parallel Phase 1b/2 trial in China.

The big picture

Corvus Pharmaceuticals is positioning soquelitinib as a potential new treatment paradigm for immune diseases, leveraging its novel ITK inhibition mechanism. The company's strategic focus on expanding into broader immunology and inflammation indications aligns with the growing demand for targeted therapies in these areas. With a robust cash position and multiple trials underway, Corvus aims to build a strong clinical evidence base to support soquelitinib's potential across large markets.

What we're watching

Trial Execution: Whether Corvus can maintain enrollment momentum in its Phase 3 PTCL and Phase 2 atopic dermatitis trials.
Regulatory Pathway: The pace at which soquelitinib advances through regulatory milestones, particularly given the Orphan Drug Designation for T cell lymphoma.
Financial Sustainability: How Corvus manages its $215.2M cash runway to support multiple clinical trials and potential future financings.